GWII
NASDAQGood Works II Acquisition Corp.
News25/Ratings0
Latest news
25 items- SECSEC Form 15-12G filed by Good Works II Acquisition Corp.15-12G - Good Works II Acquisition Corp. (0001850487) (Filer)
- SECSEC Form 25-NSE filed by Good Works II Acquisition Corp.25-NSE - Good Works II Acquisition Corp. (0001850487) (Subject)
- SECGood Works II Acquisition Corp. filed SEC Form 8-K: Other Events8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
- SECGood Works II Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
- 13D/GSEC Form SC 13G filed by Good Works II Acquisition Corp.SC 13G - Good Works II Acquisition Corp. (0001850487) (Subject)
- 13D/GSEC Form SC 13G/A filed by Good Works II Acquisition Corp. (Amendment)SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
- 13D/GSEC Form SC 13G/A filed by Good Works II Acquisition Corp. (Amendment)SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
- 13D/GSEC Form SC 13G/A filed by Good Works II Acquisition Corp. (Amendment)SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
- SECSEC Form 425 filed by Good Works II Acquisition Corp.425 - Good Works II Acquisition Corp. (0001850487) (Subject)
- 13D/GSEC Form SC 13G/A filed by Good Works II Acquisition Corp. (Amendment)SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
- SECGood Works II Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
- SECGood Works II Acquisition Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
- SECSEC Form 10-Q filed by Good Works II Acquisition Corp.10-Q - Good Works II Acquisition Corp. (0001850487) (Filer)
- SECSEC Form 425 filed by Good Works II Acquisition Corp.425 - Good Works II Acquisition Corp. (0001850487) (Subject)
- NEWSGood Works II Acquisition Corp Shares To Resume Trade At 8:30 a.m. ET
- SECGood Works II Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
- NEWSGood Works II Acquisition Corp. And Direct Biologics Sign Letter Of Intent For Potential Business CombinationOn September 27, 2022, Good Works II Acquisition Corp. (the “Company”) and Direct Biologics, Inc., a late-stage biotechnology company (“Direct Biologics”), announced the signing of a non-binding letter of intent for a potential business combination. The letter of intent is non-binding except with respect to certain specified provisions relating to, among other things, exclusivity, expenses and other customary provisions. The letter of intent provides that, until November 21, 2022, the Company and Direct Biologics will negotiate exclusively with each other to achieve a definitive agreement whereby the Company would combine with Direct Biologics, resulting in a combined publicly traded com
- PRGood Works II Acquisition Corp. and Direct Biologics, LLC Announce a Definitive Agreement for a Business CombinationGood Works II Acquisition Corp. (NASDAQ:GWII) ("Good Works II"), a publicly traded special purpose acquisition company ("SPAC"), and Direct Biologics, LLC ("Direct Biologics"), a late-stage biotechnology company, today announced the signing of a definitive agreement that, upon the satisfaction of all closing conditions, will result in Direct Biologics becoming a publicly traded company. Upon transaction close, which is expected to occur in the first half of 2023, the combined company will be named Direct Biologics, Inc. and shares of its common stock are expected to trade on the Nasdaq Capital Market. Cary Grossman, Chief Executive Officer of Good Works II, commented, "We formed Good Works
- NEWSGood Works II Acquisition Shares Halted, News Pending
- NEWSGood Works II Acquisition Corp Shares To Resume Trade At 8:30 a.m. ET
- NEWSGood Works II Acquisition Corp. Announces Letter Of Intent For A Business Combination With Direct Biologics, LLCDirect Biologics leverages a proprietary extracellular vesicle platform technology designed to harness the power of bone marrow-derived mesenchymal stem cells to develop cell-free therapeutics Product candidate, ExoFlo™, is in a Phase 3 clinical trial for treating moderate-to-severe acute respiratory distress syndrome in hospitalized adults with severe-to-critical COVID-19 Proposed transaction values Direct Biologics at an enterprise value of $675 million
- SECGood Works II Acquisition Corp. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
- PRGood Works II Acquisition Corp. Announces Letter of Intent for a Business Combination with Direct Biologics, LLCDirect Biologics leverages a proprietary extracellular vesicle platform technology designed to harness the power of bone marrow-derived mesenchymal stem cells to develop cell-free therapeutics Product candidate, ExoFlo™, is in a Phase 3 clinical trial for treating moderate-to-severe acute respiratory distress syndrome in hospitalized adults with severe-to-critical COVID-19 Proposed transaction values Direct Biologics at an enterprise value of $675 million Good Works II Acquisition Corp. (NASDAQ:GWII) ("Good Works II"), a publicly traded special purpose acquisition company ("SPAC"), and Direct Biologics, LLC ("Direct Biologics"), a late-stage biotechnology company, today announced the sig
- NEWSGood Works II Acquisition Corp. Shares Halted, News Pending
- SECSEC Form DEF 14A filed by Good Works II Acquisition Corp.DEF 14A - Good Works II Acquisition Corp. (0001850487) (Filer)